Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020
NEW YORK, Dec. 15, 2014 /PRNewswire/ -- Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany
The Glioblastoma Multiforme (GBM) treatment market is forecast to grow rapidly from $301 million in 2013 to $623 million by 2020, at a Compound Annual Growth Rate (CAGR) of 10.9%. Such significant growth comes despite the patent expiration of Temodar (temozolomide) and will be driven primarily by the market entry of the DCVax-L vaccine. This follows clinical trials showing that DCVax-L produces an Overall Survival (OS) of around 2.3 times longer than the current standard of care for newly diagnosed patients. Report Information
Angel Wong, Analyst for GBI Research, says: "The current standard treatment of surgery, radiotherapy and chemotherapy, in combination with Temodar, has an OS of less than 15 months. As DCVax-L has been shown to extend OS substantially, the vaccine will demand a premium price once it hits the market."
GBI Research expects DCVax-L, which has recently received early approval in Germany, to be approved in the US and EU in 2015 and 2016, respectively, ahead of less efficacious treatments Cotara and Rindopepimut (CDX-110), which will enter the global GBM treatment market in 2016 and 2017, respectively. DCVax-L has the added advantage of facing few other active competitors in the current high-risk GBM therapeutics market.
"Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany" assesses the current GBM therapeutics market and forecasts market trends to 2020. It analyzes key drivers and barriers, and includes an in-depth analysis of the drugs available for the treatment of GBM, a comprehensive review of the developmental pipelines and additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate.
Scope
- The report assesses the current GBM market and forecasts market trends to 2020, analyzing key drivers and barriers
- In-depth analysis of the drugs available for the treatment of GBM, including safety, efficacy, treatment patterns, and strengths and weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy
- A comprehensive review of the developmental pipeline for GBM, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period, with the pipeline analyzed by Phase distribution, molecule type and molecular target
- Additional in-depth analysis of GBM clinical trials by Phase, molecule type, trial size, trial duration and program failure rate
- Multi-scenario forecast data for the GBM market to 2020, taking into account the introduction of new drugs, the expiry of key patents and the changes in disease epidemiology across the key developed markets of the US, Canada, Japan, Germany, the UK, France, Italy and Spain
- Discussion of the drivers of and barriers to market growth
Reasons to Buy
- The report will assist business development and enable marketing executives who wish to strategize their product launches
- Understand the different levels of GBM therapies for newly diagnosed and recurrent GBM
- Understand the vast scope of the pipeline and determine which molecule types and mechanisms of action are prominent
- Observe the trends in clinical trial duration and size by clinical Phase and molecule type, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for GBM therapeutics
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the GBM therapeutics market.
Read the full report: http://www.reportlinker.com/p02234306-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/glioblastoma-multiforme-therapeutics-in-major-developed-markets-to-2020-300009812.html
SOURCE Reportlinker
Share this article